Nektar Therapeutics Announces Nktr-255 Following Cd19-Directed CAR-T Therapy Enhanced Complete Response Rates in Patients With Relapsed or Refractory Large B-Cell Lymphoma at the 66TH Annual Ash Meeting
內克塔治療宣佈Nktr-255，針對Cd19定向car-t療法在復發或難治性大b細胞淋巴瘤患者中提高了完全應答率，報道於第66屆美國血液學會年會。
